Dr. Frenkl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
West Pavilion, 3rd Floor
Philadelphia, PA 19104Phone+1 215-662-2891Fax+1 215-662-6734
Education & Training
Brown UniversityResidency, Urology, 1999 - 2003- Brown UniversityResidency, Surgery, 1998 - 1999
Duke University HospitalInternship, Transitional Year, 1996 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1996
Certifications & Licensure
PA State Medical License 2006 - 2024
NJ State Medical License 1992 - 2007
OH State Medical License 2003 - 2007
NC State Medical License 1997 - 1998- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 69 citationsDiscovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive BladderScott D. Edmondson, Cheng Zhu, Nam Fung Kar, Jerry Di Salvo, Hiroshi Nagabukuro
Journal of Medicinal Chemistry. 2016-01-08 - 234 citationsPembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, ...Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans
The Lancet. Oncology. 2021-07-01 - 154 citationsLong-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelia...Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O'Donnell, Petros Grivas
Journal of Clinical Oncology. 2020-06-17
Press Mentions
Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023- Bayer Expands Global Clinical Program for NUBEQA® (Darolutamide) in Prostate CancerMarch 23rd, 2023
- Bayer : New Data Presented at ASCO GU Confirm Survival Benefits and Favorable Safety Profile of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate CancerFebruary 20th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
